Core Viewpoint - The company, Valiant Bio (维立志博-B), has seen its stock price increase by over 4% following the announcement of its dual-specific antibody, LBL-024, receiving Fast Track designation from the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1 - Valiant Bio's LBL-024 has now received three regulatory recognitions, including Fast Track designation from the FDA, and is currently in Phase II or registration clinical trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC [1] - The Chief Medical Officer of Valiant Bio, Dr. Cai Shengli, emphasized that this latest recognition from an international regulatory authority highlights the significant clinical potential and market prospects of LBL-024 [1] - The milestone is expected to accelerate the global development process of LBL-024, facilitating its market entry and benefiting patients worldwide [1]
维立志博-B涨超4% PD-L1/4-1BB双抗获FDA快速通道资格